Saik Andrew
Insider CIK 1616284 · AUXL CFO · ICPT EVP & Chief Financial Officer · MIST Director · EDGE Chief Financial Officer, Director · MNLO Chief Financial Officer · ARVN Chief Financial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ARVN ARVINAS, INC. | S Sale | 2026-06-24 | 2026-06-24 | 5,696 | $8.16 | $46.5K | 187,432 | SEC↗ |
| MIST Milestone Pharmaceuticals | A Award deriv | 2026-06-10 | 2026-06-12 | 77,000 | — | $0 | 77,000 | SEC↗ |
| ARVN ARVINAS, INC. | S Sale | 2026-05-11 | 2026-05-13 | 11,139 | $9.94 | $110.7K | 193,128 | SEC↗ |
| ARVN ARVINAS, INC. | A Award deriv | 2026-02-26 | 2026-03-02 | 67,000 | — | $0 | 67,000 | SEC↗ |
| ARVN ARVINAS, INC. | A Award | 2026-02-26 | 2026-03-02 | 45,000 | — | $0 | 204,267 | SEC↗ |
| ARVN ARVINAS, INC. | S Sale | 2026-02-13 | 2026-02-18 | 5,134 | $11.89 | $61.0K | 159,267 | SEC↗ |
| ARVN ARVINAS, INC. | S Sale | 2025-06-24 | 2025-06-24 | 5,700 | $7.61 | $43.4K | 164,401 | SEC↗ |
| MIST Milestone Pharmaceuticals | A Award deriv | 2025-06-10 | 2025-06-12 | 40,000 | — | $0 | 40,000 | SEC↗ |
| ARVN ARVINAS, INC. | A Award deriv | 2025-05-09 | 2025-05-13 | 91,000 | — | $0 | 91,000 | SEC↗ |
| ARVN ARVINAS, INC. | A Award | 2025-05-09 | 2025-05-13 | 59,600 | — | $0 | 170,101 | SEC↗ |
| ARVN ARVINAS, INC. | A Award deriv | 2025-02-13 | 2025-02-18 | 74,960 | — | $0 | 74,960 | SEC↗ |
| ARVN ARVINAS, INC. | A Award | 2025-02-13 | 2025-02-18 | 49,092 | — | $0 | 110,501 | SEC↗ |
| MIST Milestone Pharmaceuticals | A Award deriv | 2024-08-28 | 2024-08-29 | 40,000 | — | $0 | 40,000 | SEC↗ |
| MIST Milestone Pharmaceuticals | A Award deriv | 2024-07-15 | 2024-07-17 | 80,000 | — | $0 | 80,000 | SEC↗ |
| ARVN ARVINAS, INC. | A Award deriv | 2024-06-24 | 2024-06-26 | 94,418 | — | $0 | 94,418 | SEC↗ |
| ARVN ARVINAS, INC. | A Award | 2024-06-24 | 2024-06-26 | 61,409 | — | $0 | 61,409 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | D To issuer deriv | 2023-11-08 | 2023-11-13 | 72,540 | — | $0 | 0 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | D To issuer deriv | 2023-11-08 | 2023-11-13 | 17,600 | — | $0 | 0 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | D To issuer deriv | 2023-11-08 | 2023-11-13 | 24,000 | — | $0 | 0 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | U Tender | 2023-11-08 | 2023-11-13 | 23,021 | $19.00 | $437.4K | 0 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | D To issuer | 2023-11-08 | 2023-11-13 | 45,244 | $19.00 | $859.6K | 0 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | F Tax w/h | 2023-09-21 | 2023-09-25 | 908 | $10.80 | $9.8K | 68,265 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | F Tax w/h | 2023-06-21 | 2023-06-23 | 908 | $11.74 | $10.7K | 69,173 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | F Tax w/h | 2023-03-21 | 2023-03-23 | 909 | $14.19 | $12.9K | 70,081 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | A Award deriv | 2023-01-27 | 2023-01-31 | 24,000 | — | $0 | 24,000 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | A Award | 2023-01-27 | 2023-01-31 | 14,700 | — | $0 | 70,990 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | F Tax w/h | 2022-12-31 | 2023-01-03 | 718 | $12.37 | $8.9K | 56,290 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | F Tax w/h | 2022-12-21 | 2022-12-23 | 908 | $13.43 | $12.2K | 57,008 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | F Tax w/h | 2022-09-21 | 2022-09-23 | 908 | $14.85 | $13.5K | 57,916 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | F Tax w/h | 2022-06-21 | 2022-06-23 | 3,632 | $12.48 | $45.3K | 58,824 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | A Award deriv | 2022-01-27 | 2022-01-31 | 17,600 | — | $0 | 17,600 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | A Award | 2022-01-27 | 2022-01-31 | 10,300 | — | $0 | 62,456 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | A Award deriv | 2021-06-21 | 2021-06-22 | 72,540 | — | $0 | 72,540 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS, | A Award | 2021-06-21 | 2021-06-22 | 52,156 | — | $0 | 52,156 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | A Award | 2021-05-28 | 2021-06-02 | 3,017 | $3.36 | $10.1K | 116,468 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | F Tax w/h | 2021-03-31 | 2021-04-02 | 762 | $6.84 | $5.2K | 113,451 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | A Award deriv | 2021-02-22 | 2021-02-24 | 68,162 | — | $0 | 68,162 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | A Award | 2021-02-22 | 2021-02-24 | 29,213 | — | $0 | 114,213 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | P Buy | 2020-09-08 | 2020-09-08 | 40,000 | $1.46 | $58.4K | 340,000 | SEC↗ |
| MNLO Menlo Therapeutics Inc. | A Award deriv | 2020-05-06 | 2020-05-08 | 250,000 | — | $0 | 250,000 | SEC↗ |
| MNLO Menlo Therapeutics Inc. | A Award | 2020-05-06 | 2020-05-08 | 250,000 | — | $0 | 300,000 | SEC↗ |
| MNLO Menlo Therapeutics Inc. | A Award deriv | 2020-03-23 | 2020-03-24 | 100,000 | — | $0 | 100,000 | SEC↗ |
| MNLO Menlo Therapeutics Inc. | A Award | 2020-03-23 | 2020-03-24 | 50,000 | — | $0 | 50,000 | SEC↗ |
| PDSB PDS Biotechnology Corp | A Award | 2020-02-14 | 2020-02-19 | 38,400 | $1.30 | $49.9K | 42,549 | SEC↗ |
| PDSB PDS Biotechnology Corp | A Award deriv | 2019-06-06 | 2019-06-07 | 62,715 | — | $0 | 62,715 | SEC↗ |
| EDGE Edge Therapeutics, Inc. | M Exercise deriv | 2019-03-15 | 2019-03-18 | 82,999 | — | $0 | 0 | SEC↗ |
| EDGE Edge Therapeutics, Inc. | M Exercise | 2019-03-15 | 2019-03-18 | 82,999 | — | $0 | 82,999 | SEC↗ |
| EDGE Edge Therapeutics, Inc. | A Award deriv | 2018-08-14 | 2018-08-15 | 82,999 | — | $0 | 82,999 | SEC↗ |
| EDGE Edge Therapeutics, Inc. | A Award deriv | 2018-06-19 | 2018-06-20 | 166,001 | — | $0 | 166,001 | SEC↗ |
| EDGE Edge Therapeutics, Inc. | A Award deriv | 2018-03-01 | 2018-03-05 | 50,000 | — | $0 | 50,000 | SEC↗ |
| EDGE Edge Therapeutics, Inc. | A Award deriv | 2017-11-01 | 2017-11-03 | 200,000 | — | $0 | 200,000 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | J Other deriv | 2015-01-29 | 2015-01-30 | 165,000 | $36.53 | $6.03M | 0 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | J Other | 2015-01-29 | 2015-01-30 | 10,000 | $36.53 | $365.3K | 0 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | A Award deriv | 2014-08-18 | 2014-08-20 | 165,000 | — | $0 | 165,000 | SEC↗ |
| AUXL AUXILIUM PHARMACEUTICALS I | A Award | 2014-08-18 | 2014-08-20 | 10,000 | — | $0 | 10,000 | SEC↗ |